<DOC>
	<DOCNO>NCT03020810</DOCNO>
	<brief_summary>This single patient expand access , compassionate non-emergency use study provide patient severe asthma , qualify ongoing clinical trial dupilumab , access investigational treatment .</brief_summary>
	<brief_title>Dupilumab Compassionate Use Study</brief_title>
	<detailed_description>This study undertaken determine whether dupilumab efficacy extremely severe asthma , allow severe asthma patient , try nearly every immunosuppressive drug , early access potentially effective therapy . The patient continue study indefinitely . Safety evaluate serious adverse event report .</detailed_description>
	<criteria>Sever systemic corticosteroid dependent asthma 5 year Disease asthma Circulation eosinophils 1500/ul Current smoker 10 pack year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>